|
gptkbp:instanceOf
|
gptkb:company
|
|
gptkbp:CEO
|
gptkb:Thomas_Clozel
|
|
gptkbp:collaboratesWith
|
academic medical centers
pharmaceutical companies
|
|
gptkbp:focusArea
|
cardiology
oncology
rare diseases
|
|
gptkbp:foundedYear
|
2016
|
|
gptkbp:founder
|
gptkb:Gilles_Wainrib
gptkb:Thomas_Clozel
|
|
gptkbp:headquartersLocation
|
gptkb:New_York_City
gptkb:Paris
|
|
https://www.w3.org/2000/01/rdf-schema#label
|
Owkin
|
|
gptkbp:industry
|
gptkb:artificial_intelligence
healthcare
|
|
gptkbp:investedIn
|
gptkb:Cathay_Innovation
gptkb:Sanofi
gptkb:GV_(Google_Ventures)
gptkb:BPI_France
gptkb:Eight_Roads_Ventures
|
|
gptkbp:mission
|
improve drug discovery and patient care using AI
|
|
gptkbp:notableProject
|
gptkb:MELLODDY
gptkb:Owkin_Data_Network
gptkb:Owkin_Studio
|
|
gptkbp:numberOfEmployees
|
over 200
|
|
gptkbp:specializesIn
|
federated learning
AI for medical research
machine learning for drug discovery
|
|
gptkbp:status
|
gptkb:Dragon
|
|
gptkbp:valuation
|
over $1 billion
|
|
gptkbp:website
|
https://owkin.com
|
|
gptkbp:bfsParent
|
gptkb:Substra
gptkb:Cathay_Innovation
gptkb:Korelya_Capital
|
|
gptkbp:bfsLayer
|
7
|